SNDL - SNDL Inc.
Many marijuana stock investors have a strong positive outlook on the future of the market. If you've been watching the cannabis sector, then you know how volatile and uncertain trading can be. Yet there have been changes that give more upside to what the future of investing can hold. As cannabis is now a class 3 substance federally, more companies are making shifts in their business to get in line with this new legislation.
SNDL faces pressure after Q1 results show falling sales, weak cannabis demand, and margin strain, raising concerns about growth in a saturated Canadian market.
Every cannabis trader's feed is buzzing about SNDL (NASDAQ:SNDL) because the company's Q1 2026 release on April 28, 2026 delivered a tidy little EPS beat that retail can rally around.
SNDL Inc. (SNDL) Q1 2026 Earnings Call Transcript
The Company Maintains Strong Liquidity and Advances Strategic Priorities and Profit-Enhancement Initiatives The Company Maintains Strong Liquidity and Advances Strategic Priorities and Profit-Enhancement Initiatives
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises SNDL, Inc., (“SNDL" or the "Company") (NASDAQ: SNDL) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F.
EDMONTON, Alberta, April 15, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) ("SNDL") announced today that it will release its first quarter 2026 financial results for the period ended March 31, 2026, before markets open on Wednesday, April 29, 2026.
SNDL Inc. (NASDAQ:SNDL) currently trades at $1.36, while the average analyst price target sits at $4.70, implying an upside of roughly 245% from current levels.
The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result, investors are closely watching key names for potential upside during sector recoveries.
SNDL (NASDAQ: SNDL - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability. Risk and Volatility SNDL has a beta of 0.81,
NEW YORK & LOS ANGELES--(BUSINESS WIRE)--Sundial Media & Technology Group (SMTG), a human connections platform and the parent company of iconic brands like ESSENCE and Refinery29, has appointed Amanda Butler as its first-ever Chief Marketing Officer to lead the integration and evolution of marketing strategy across SMTG's portfolio, overseeing Consumer Marketing, Communications, Creative Strategy, Insights, and evolving Content Production into a full-scale studio. Her role elevates marketin.
EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL's current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
The cannabis industry has made a tremendous impact on the world. From being once a taboo subject to now a well-respected and much more accepted industry. Even the thought of what may happen to a legal operator could shape the way marijuana stock investors think. At one point during the green rush, the fear of what could happen with no federal reform would shift how the market reacted. But as of 2026, those fears and worries have calmed down a lot.
SNDL showed improved financial performance for Q4-2025 with net income and free cash flow. The company maintains a strong balance sheet with no debt. SNDL has US cannabis assets and international operations, but there are currently no new synergies boosting performance.
SNDL remains rated hold after a lackluster Q4, with no compelling catalyst to upgrade to buy. SNDL trades at a discount to tangible book value and maintains a debt-free, cash-rich balance sheet, supporting downside protection. Valuation appears fair at 4.3x 2026E adjusted EBITDA, with peer multiples notably higher, but sector-wide challenges persist.
SNDL Inc. (SNDL) Q4 2025 Earnings Call Transcript
The Company Reports Record Full-Year Income Statement Performance and Cash Generation The Company Reports Record Full-Year Income Statement Performance and Cash Generation
SNDL (NASDAQ: SNDL - Get Free Report) and Metastat (OTCMKTS:MTST - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk SNDL has a beta of 0.73, suggesting
Marijuana stocks, even with their volatile behavior, still offer diverse investment opportunities. Not every sector or company deals directly with the plant, so investors see this as an opportunity to capitalize. Now, even with that said, MSO and companies that work directly with the plant tend to capture more market share. Also, they are usually the first to see a run in trading when the time comes.
Shares of SNDL Inc. SNDL, one of the largest vertically integrated cannabis players in Canada, have been declining steadily over the past six months.